Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

English (EN)·Polski (PL)·Ukraiński (UK)
Go to the home page of the library Uniwersytet Ekonomiczny we Wrocławiu Link opens in a new window Library logo Prolib Integro - home pageUniwersytet Ekonomiczny we Wrocławiu
Title of the item:

Managing common endocrine disorders amid COVID-19 pandemic.

Title:
Managing common endocrine disorders amid COVID-19 pandemic.
Authors:
Pal R; Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Bhadada SK; Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: .
Source:
Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2020 Sep - Oct; Vol. 14 (5), pp. 767-771. Date of Electronic Publication: 2020 Jun 04.
Publication Type:
Journal Article; Review
Language:
English
Imprint Name(s):
Original Publication: Amsterdam : Elsevier Ltd.
MeSH Terms:
Pandemics*
Coronavirus Infections/*epidemiology
Endocrine System Diseases/*therapy
Endocrinology/*methods
Pneumonia, Viral/*epidemiology
Betacoronavirus/physiology ; COVID-19 ; Coronavirus Infections/complications ; Endocrine System Diseases/complications ; Endocrine System Diseases/epidemiology ; Endocrinology/organization & administration ; Endocrinology/trends ; Humans ; Pneumonia, Viral/complications ; Practice Guidelines as Topic ; SARS-CoV-2
References:
Postgrad Med J. 2020 Jul;96(1137):429-430. (PMID: 32234837)
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):273-276. (PMID: 32283497)
Diabetes Res Clin Pract. 2020 Apr;162:108132. (PMID: 32234504)
Indian J Endocrinol Metab. 2012 May;16(3):489-91. (PMID: 22629541)
Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185. (PMID: 29229498)
Nat Rev Endocrinol. 2018 May;14(5):301-316. (PMID: 29569622)
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):351-354. (PMID: 32311652)
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):513-517. (PMID: 32388331)
Eur J Endocrinol. 2020 Aug;183(2):G57-G65. (PMID: 32396134)
Eur J Clin Nutr. 2020 Jun;74(6):856-859. (PMID: 32398871)
J Clin Endocrinol Metab. 2020 May 1;105(5):. (PMID: 32232480)
Diabetes Res Clin Pract. 2019 Nov;157:107843. (PMID: 31518657)
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. (PMID: 26222757)
J Endocrinol Invest. 2020 Aug;43(8):1141-1147. (PMID: 32335855)
Nat Rev Endocrinol. 2019 Jul;15(7):417-427. (PMID: 30850749)
Osteoporos Int. 2003 Aug;14(8):677-82. (PMID: 12879220)
J Bone Miner Res. 2018 Feb;33(2):211-220. (PMID: 28975661)
Eur J Endocrinol. 2018 May;178(5):447-458. (PMID: 29472378)
J Diabetes Sci Technol. 2020 Jul;14(4):714-715. (PMID: 32438820)
Eur J Endocrinol. 2020 Jul;183(1):G33-G39. (PMID: 32438340)
Osteoporos Int. 2020 Jul;31(7):1189-1191. (PMID: 32346775)
J Clin Endocrinol Metab. 2020 Feb 1;105(2):. (PMID: 31532828)
Neurosurgery. 2020 Jul 1;87(1):E66-E67. (PMID: 32293678)
Nature. 2005 Jul 7;436(7047):112-6. (PMID: 16001071)
Eur J Endocrinol. 2020 Jul;183(1):G1-G7. (PMID: 32380475)
Endocr Rev. 2015 Dec;36(6):622-45. (PMID: 26414232)
Eur J Endocrinol. 2013 Mar 15;168(4):609-14. (PMID: 23384710)
J Clin Endocrinol Metab. 2016 Dec;101(12):4843-4850. (PMID: 27623069)
Diabetes Res Clin Pract. 2020 May;163:108146. (PMID: 32283128)
Eur J Endocrinol. 2020 Jul;183(1):G17-G23. (PMID: 32369770)
Eur J Endocrinol. 2020 Jul;183(1):G25-G32. (PMID: 32379699)
Lancet Diabetes Endocrinol. 2020 Jul;8(7):570. (PMID: 32445630)
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310. (PMID: 32298981)
Contributed Indexing:
Keywords: COVID-19; Calcium-related disorders; Cushing’s syndrome; Diabetes mellitus; Endocrine disorders; Osteoporosis; Pituitary tumors; Primary adrenal insufficiency
Entry Date(s):
Date Created: 20200611 Date Completed: 20200924 Latest Revision: 20231111
Update Code:
20240104
PubMed Central ID:
PMC7271862
DOI:
10.1016/j.dsx.2020.05.050
PMID:
32521463
Academic Journal
Full Text Finder
Background and Aims: The novel coronavirus disease (COVID-19) pandemic and the resulting nationwide lockdowns have posed a major challenge to the management of pre-existing and newly diagnosed endocrine disorders. Herein, we have summarized the management approaches of common endocrine disorders amid the ongoing pandemic.
Methods: We have performed an extensive literature search for articles in PubMed, EMBASE and Google Scholar databases till 25 May 2020, with the following keywords: "COVID-19", "diabetes mellitus", "thyroid disorders", "primary adrenal insufficiency", "Cushing's syndrome", "pituitary tumors", "vitamin D″", "osteoporosis", "primary hyperparathyroidism", "hypoparathyroidism", "management", "treatment" and "guidelines" with interposition of the Boolean operator "AND".
Results: We have summarized the most feasible strategies for the management of diabetes mellitus, thyroid disorders, primary adrenal insufficiency (including congenital adrenal hyperplasia), Cushing's syndrome, pituitary tumors, osteoporosis, primary hyperparathyroidism and hypoparathyroidism amid the constraints laid down by the raging pandemic. In general, medical management should be encouraged and surgical interventions should be deferred whenever possible. Ongoing medications should be continued. Sick-day rules should be sincerely adhered to. Regular contact with physicians can be maintained through teleconsultations and virtual clinics.
Conclusions: Considering the burden of endocrine disorders in the general population, their management needs to be prioritized amid the ongoing COVID-19 pandemic.
Competing Interests: Declaration of competing interest None
(Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.)

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.